Pfizer's experimental drug slows incurable breast cancer, findings show

 

Pfizer's experimental breast cancer drug stopped progression of an incurable form of the disease for more than two years in a study, a dramatic delay for those with the second deadliest cancer in women.

Patients were given the medicine, called PD 0332991, along with Novartis's Femara. The findings, reported Wednesday at the San Antonio Breast Cancer Symposium in Texas, showed no tumor progression for a median of 26.1 months, compared with 7.5 months in those who received Femara alone. Results were from the second of three stages of testing normally needed for U.S. approval.

The medicine is the first in a new class of agents that works by blocking a protein critical in the cancer cell cycle, said lead researcher Richard Finn. It's also among the most promising in New York-based Pfizer's drug development pipeline, with the potential for generating $5 billion in annual sales for breast and other tumor types, Andrew Baum, an analyst at Citigroup in London, wrote in a note to investors.

"This magnitude of benefit is probably one of the largest with any new agent in breast cancer, or perhaps any solid tumor," Finn, an associate professor of medicine at the Jonsson Comprehensive Cancer Center at the University of California, Los Angeles, said in a telephone interview. "It's dramatic to see this level of benefit with a new agent."

The findings are noteworthy because of the size of the benefit and comparative safety of the experimental treatment, said Claudine Isaacs, an oncologist and professor of medicine at Georgetown Lombardi Comprehensive Cancer Center in Washington. The study, involving 165 patients with metastatic disease, was small and must be confirmed in larger trials, she said.

The study included women with tumors fueled by the hormone estrogen, the most common type of breast cancer. All had metastatic disease, which had spread to other parts of the body and is no longer considered curable.

Breast cancer is the most common tumor in women. Almost 230,000 women in the United States will be diagnosed with it this year, and more than 39,900 will die from it, according to the American Cancer Society. Lung cancer is the deadliest form of the disease for women.

"It does make you stop and look," Isaacs said in a telephone interview. The results are "much more marked than we typically see. It's hard to ignore that," she said. "It's not something that is changing practice today, but it's definitely something to keep one's eye on."

Investors have overlooked the drug's "mega-blockbuster potential," said Baum, the Citigroup analyst. Pfizer is at least two years ahead of its closest competitors, Eli Lilly & Co. and Novartis, with similar cancer drugs in development, he said in his Nov. 29 investment note.

 

Pfizer rose 1.9 percent to $25.64 at 4 p.m. New York time. The shares have gained 29 percent in the past 12 months. Onyx Pharmaceuticals Inc., which licensed rights to the experimental drug to Pfizer, rose 3.4 percent to $77.05.

 

The results presented Wednesday stem from an interim review of the data and come on top of potent treatment, Finn said.

Forty-five percent of patients given the drug combination responded to therapy, compared with 31 percent given Femara alone. When the researchers included women who had stable disease for six months or more, 70 percent given both drugs benefited, compared with 44 percent of those given Femara.

Pfizer is moving the compound into the final stage of testing needed for approval as quickly as possible, with an international trial in the same type of cancer slated to begin next year, said Mace Rothenberg, senior vice president of clinical development in the company's oncology unit. Additional research is examining other types of tumors, he said.

The company is also talking to regulators to determine what kind of information will be needed to win marketing approval of the medicine, he said in a telephone interview. While the Food and Drug Administration typically requires two studies confirming the benefits of an investigational agent, it has leeway to expedite the process for promising drugs.

About one in three patients needed to have their dose of the experimental drug lowered during the study. Side effects included low levels of infection-fighting white blood cells, anemia and fatigue, though there weren't any serious cases of fever tied to the low white blood cells.

The first 66 patients were post-menopausal women with estrogen-receptor positive cancer. The second 99 patients also had tumors that were fueled by estrogen, though they had genetic alterations the researchers hoped could further identify people who would benefit from the therapy.

About half the women were initially diagnosed with advanced disease and hadn't gotten previous drug treatment. The other half had previously received chemotherapy or treatment after surgery to remove the tumor, Finn said. Laboratory work conducted before the study began suggested the Pfizer medicine was particularly potent against estrogen-receptor positive cancers.

There were no differences in response among women with the biomarkers and those who didn't have them, Finn said. Both sets of patients had a significant benefit.

"The drug obviously hits a critical pathway in estrogen- receptor positive breast cancer," he said. "If we took triple negative breast cancer, we wouldn't expect this result."

Pfizer is reaching out to cancer experts to help devise the most efficient studies to answer questions about when and how the drug should be given, and what other medicines should be given with it to maximize the benefit, Rothenberg said.

"It's an irony of having a drug moving forward as quickly as we can," Rothenberg said. "There will be gaps in our knowledge of how to give it and when. We're trying to move forward with a thoughtful, methodical approach."

The study targeted women who were newly diagnosed with metastatic, or spreading, breast cancer. There are several other effective treatments available even after the experimental compound stops working, Finn said.

"The magnitude of this benefit I don't think should be underestimated," Finn said. "These are patients who have incurable breast cancer. A lot of drugs in oncology have been approved or are getting a lot of traction because of improvements that last weeks to a few months. We have gone from 7 months to 26 months. That's groundbreaking."

Life and Style
Swimsuit, £245, by Agent Provocateur
fashion

Diving in at the deep end is no excuse for shirking the style stakes

Sport
Mario Balotelli, Divock Origi, Loic Remy, Wilfried Bony and Karim Benzema
transfersBony, Benzema and the other transfer targets
Sport
There were mass celebrations across Argentina as the country's national team reached their first World Cup final for 24 years
transfersOne of the men to suffer cardiac arrest was 16 years old
Life and Style
lifeHere's one answer to an inquisitive Reddit user's question
PROMOTED VIDEO
Have you tried new the Independent Digital Edition apps?
News
ebookA unique anthology of reporting and analysis of a crucial period of history
News
peopleDave Legeno, the actor who played werewolf Fenrir Greyback in the Harry Potter films, has died
News
Detail of the dress made entirely of loom bands
news
Life and Style
beauty
Arts and Entertainment
Armando Iannucci, the creator of 'The Thick of It' says he has
tvArmando Iannucci to concentrate on US show Veep
Sport
German supporters (left) and Argentina fans
world cup 2014Final gives England fans a choice between to old enemies
Arts and Entertainment
A still from the worldwide Dawn of the Planet of the Apes trailer debut
film
News
peopleMario Balotelli poses with 'shotgun' in controversial Instagram pic
News
A mugshot of Ian Watkins released by South Wales Police following his guilty pleas
peopleBandmates open up about abuse
Sport
Basketball superstar LeBron James gets into his stride for the Cleveland Cavaliers
sportNBA superstar announces decision to return to Cleveland Cavaliers
Sport
Javier Mascherano of Argentina tackles Arjen Robben of the Netherlands as he attempts a shot
world cup 2014
Arts and Entertainment
The successful ITV drama Broadchurch starring David Tenant and Olivia Coleman came to an end tonight
tv
Sport
Four ski officials in Slovenia have been suspended following allegations of results rigging
sportFour Slovenian officials suspended after allegations they helped violinist get slalom place
News
14 March 2011: George Clooney testifies before the Senate Foreign Relations Committee during a hearing titled 'Sudan and South Sudan: Independence and Insecurity.' Clooney is co-founder of the Satellite Sentinel Project which uses private satellites to collect evidence of crimes against civilian populations in Sudan
people
Arts and Entertainment
Balaban is indirectly responsible for the existence of Downton Abbey, having first discovered Julian Fellowes' talents as a screenwriter
tvCast members told to lose weight after snacking on set
Life and Style
More than half of young adults have engaged in 'unwanted but consensual sexting with a committed partner,' according to research
tech
Life and Style
A binge is classed as four or more alcoholic drinks for women and five or more for men, consumed over a roughly two-hour period
tech
Independent
Travel Shop
the manor
Up to 70% off luxury travel
on city breaks Find out more
santorini
Up to 70% off luxury travel
on chic beach resorts Find out more
sardina foodie
Up to 70% off luxury travel
on country retreats Find out more
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs General

Biztalk - outstanding opportunity

£75000 - £85000 per annum + ex bens: Deerfoot IT Resources Limited: Biztalk Te...

Trade Desk Specialist (FIX, Linux, Windows, Network Security)

£60000 per annum: Harrington Starr: Trade Desk Specialist (FIX, Linux, Windows...

Service Desk Analyst (Windows, Active Directory, ITIL, Reuter)

£35000 per annum: Harrington Starr: Service Desk Analyst (Windows, Active Dire...

PHP Web Developer (HTML5, CSS3, Jenkins, Vagrant, MySQL)

£40000 - £45000 per annum + Benefits + Bonus: Harrington Starr: PHP Web Develo...

Day In a Page

A History of the First World War in 100 Moments: Peace without magnanimity - the summit in a railway siding that ended the fighting

A History of the First World War in 100 Moments

Peace without magnanimity - the summit in a railway siding that ended the fighting
Scottish independence: How the Commonwealth Games could swing the vote

Scottish independence: How the Commonwealth Games could swing the vote

In the final part of our series, Chris Green arrives in Glasgow - a host city struggling to keep the politics out of its celebration of sport
Out in the cold: A writer spends a night on the streets and hears the stories of the homeless

A writer spends a night on the streets

Rough sleepers - the homeless, the destitute and the drunk - exist in every city. Will Nicoll meets those whose luck has run out
Striking new stations, high-speed links and (whisper it) better services - the UK's railways are entering a new golden age

UK's railways are entering a new golden age

New stations are opening across the country and our railways appear to be entering an era not seen in Britain since the early 1950s
Conchita Wurst becomes a 'bride' on the Paris catwalk - and proves there is life after Eurovision

Conchita becomes a 'bride' on Paris catwalk

Alexander Fury salutes the Eurovision Song Contest winner's latest triumph
Pétanque World Championship in Marseilles hit by

Pétanque 'world cup' hit by death threats

This year's most acrimonious sporting event took place in France, not Brazil. How did pétanque get so passionate?
Whelks are healthy, versatile and sustainable - so why did we stop eating them in the UK?

Why did we stop eating whelks?

Whelks were the Victorian equivalent of the donor kebab and our stocks are abundant. So why do we now export them all to the Far East?
10 best women's sunglasses

In the shade: 10 best women's sunglasses

From luxury bespoke eyewear to fun festival sunnies, we round up the shades to be seen in this summer
Germany vs Argentina World Cup 2014: Lionel Messi? Javier Mascherano is key for Argentina...

World Cup final: Messi? Mascherano is key for Argentina...

No 10 is always centre of attention but Barça team-mate is just as crucial to finalists’ hopes
Siobhan-Marie O’Connor: Swimmer knows she needs Glasgow joy on road to Rio

Siobhan-Marie O’Connor: Swimmer needs Glasgow joy on road to Rio

18-year-old says this month’s Commonwealth Games are a key staging post in her career before time slips away
The true Gaza back-story that the Israelis aren’t telling this week

The true Gaza back-story that the Israelis aren’t telling this week

A future Palestine state will have no borders and be an enclave within Israel, surrounded on all sides by Israeli-held territory, says Robert Fisk
A History of the First World War in 100 Moments: The German people demand an end to the fighting

A History of the First World War in 100 Moments

The German people demand an end to the fighting
New play by Oscar Wilde's grandson reveals what the Irish wit said at his trials

New play reveals what Oscar Wilde said at trials

For a century, what Wilde actually said at his trials was a mystery. But the recent discovery of shorthand notes changed that. Now his grandson Merlin Holland has turned them into a play
Can scientists save the world's sea life from

Can scientists save our sea life?

By the end of the century, the only living things left in our oceans could be plankton and jellyfish. Alex Renton meets the scientists who are trying to turn the tide
Richard III, Trafalgar Studios, review: Martin Freeman gives highly intelligent performance

Richard III review

Martin Freeman’s psychotic monarch is big on mockery but wanting in malice